Predictors of Fracture While on Treatment With Oral Bisphosphonates: A Population‐Based Cohort Study
暂无分享,去创建一个
C. Cooper | A. Díez-Pérez | N. Arden | M. Javaid | A. Judge | X. Nogués | D. Prieto-Alhambra | G. Wallace | A. Pagès-Castellà | A. Pagès‐Castellà
[1] A. Díez-Pérez,et al. The association between fracture site and obesity in men: A population‐Based cohort study , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] Simon G A Brown. Treatment failure in osteoporosis. , 2012, Menopause international.
[3] A. Díez-Pérez,et al. “Burden of osteoporotic fractures in primary health care in Catalonia (Spain): a population-based study” , 2012, BMC Musculoskeletal Disorders.
[4] A. Díez-Pérez,et al. Risk factors for prediction of inadequate response to antiresorptives , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[5] A. Díez-Pérez,et al. The association between fracture and obesity is site‐dependent: A population‐based study in postmenopausal women , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] C. Cooper,et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.
[7] M. Grau,et al. Validez del Sistema de Información para el Desarrollo de la Investigación en Atención Primaria (SIDIAP) en el estudio de enfermedades vasculares: estudio EMMA , 2012 .
[8] R. Eastell,et al. Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study , 2012, Osteoporosis International.
[9] J. Marrugat,et al. Validity for use in research on vascular diseases of the SIDIAP (Information System for the Development of Research in Primary Care): the EMMA study. , 2012, Revista espanola de cardiologia.
[10] F. Vries. Inverse Association Between Duration of Use of Acid-Suppressive Medications and Fracture Risk , 2011 .
[11] R. Eastell,et al. Proton pump inhibitor use and the antifracture efficacy of alendronate. , 2011, Archives of internal medicine.
[12] O. Ström,et al. The societal burden of poor persistence to treatment of osteoporosis in Sweden. , 2011, Bone.
[13] Daniel Prieto-Alhambra,et al. Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). , 2011, Informatics in primary care.
[14] A. Westfall,et al. Improving the Prediction of Medication Compliance: The Example of Bisphosphonates for Osteoporosis , 2009, Medical care.
[15] J. LeLorier,et al. Differences in persistence among different weekly oral bisphosphonate medications , 2009, Osteoporosis International.
[16] S. Adami,et al. Osteoporosis treatment and fracture incidence: the ICARO longitudinal study , 2008, Osteoporosis International.
[17] C. Cooper,et al. Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO) , 2008, Osteoporosis International.
[18] S. Boonen,et al. Zoledronic acid and clinical fractures and mortality after hip fracture. , 2007, The New England journal of medicine.
[19] Steven Boonen,et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.
[20] S. Adami,et al. Fracture Incidence and Characterization in Patients on Osteoporosis Treatment: The ICARO Study , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[21] O. Johnell,et al. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures , 2006, Osteoporosis International.
[22] C. Cooper,et al. Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). , 2006, QJM : monthly journal of the Association of Physicians.
[23] B. Ettinger,et al. Persistence with weekly alendronate therapy among postmenopausal women , 2006, Osteoporosis International.
[24] G. Dalsky,et al. Differential Effects of Teriparatide and Alendronate on Bone Remodeling in Postmenopausal Women Assessed by Histomorphometric Parameters , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[25] Krista F. Huybrechts,et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice , 2004, Osteoporosis International.
[26] S. Cummings,et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. , 2000, The Journal of clinical endocrinology and metabolism.
[27] H K Genant,et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.
[28] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .